What results are realistic on Zepbound
In the 72-week SURMOUNT-1 trial, adults without diabetes lost an average of 20.9% of their body weight on the top 15 mg dose — about 48 pounds for the average participant — versus 3.1% on placebo. That’s the largest average weight loss of any approved weight-management medication to date.
Read that sentence carefully, because the important words are “average” and “trial.” SURMOUNT-1 was a supervised study: participants took a titrated weekly dose plus a reduced-calorie diet and increased activity, with regular clinician contact over 72 weeks. The 20.9% is what the group averaged under those conditions — not a number the drug guarantees you personally. Some people lost far more; some lost far less; some stopped early. About 1 in 3 people on the higher doses lost 25% or more.
Zepbound weight-loss timeline
Weight loss on Zepbound isn’t linear, and the early weeks are the most misunderstood part. You start at 2.5 mg — a dose meant to help your body adjust, not to drive weight loss — and step up every four weeks or more. The real work happens once you reach a maintenance dose, which is months in.
Here’s a realistic arc. Only the 72-week endpoint is a trial-reported average; every earlier row is an illustrative range, not a promise, and is flagged for verification.
| Trial | Dose | Duration | Avg. weight loss | Studied in |
|---|---|---|---|---|
| Weeks 1–4 (2.5 mg) | 2.5 mg | Month 1 | appetite change; ~1–3% ⚠ | Starting dose — mostly appetite and water shifts, not fat loss |
| Weeks 5–12 (5 mg ramp) | 5 mg | Months 2–3 | ~6–8% by wk 12 ⚠ | First maintenance dose; steadier weekly loss begins |
| Months 4–6 (7.5–10 mg) | 7.5–10 mg | Months 4–6 | ~10–15% ⚠ | Dose climbing toward an effective level |
| Months 7–12 (10–15 mg) | 10–15 mg | Months 7–12 | ~15–20% ⚠ | Approaching the trial-average range |
| SURMOUNT-1 endpoint (15 mg) | 15 mg | 72 weeks | 20.9% (~48 lb) | Trial-reported average, adults with obesity, no diabetes |
Two honest caveats. First, the scale often moves fast in the first week or two — some of that is water and gut changes, not fat. Second, plateaus are normal: weeks where nothing moves don’t mean the drug stopped working. The dosage page walks through the full titration schedule.
What Zepbound before-and-after photos actually show (and don’t)
A before-and-after photo is an anecdote wearing the costume of evidence. Even a completely genuine one can’t tell you the things that determine whether it applies to you.
- You’re seeing selected results. People post transformations that went well. The person who lost 6% and quit at month three, or stopped for side effects, rarely posts a montage. That selection bias inflates what looks typical.
- A photo has no timeframe or dose. Was that 12 weeks or 18 months? On 5 mg or 15 mg? With a trainer and a dietitian, or not? The picture strips out every variable that actually drives the number.
- A photo can’t separate fat from muscle. Rapid weight loss on this drug class takes lean mass along with fat unless protein intake and resistance training are deliberate. Two people down “40 pounds” can have very different body composition — and the scale won’t tell you which you’ll be. Our guide to muscle loss on GLP-1s covers how to protect against that.
Why individual results vary
Two people can start Zepbound the same week and land in very different places at week 72. The main reasons:
- The dose you reach. SURMOUNT-1 averaged 15% on 5 mg and 20.9% on 15 mg. Where you stabilize — for tolerance, side effects, or supply — shapes your ceiling.
- Starting weight and BMI. A higher starting weight usually means more total pounds lost, even at the same percentage. Percent and pounds are different stories.
- Diet and protein. The trial paired the drug with a reduced-calorie diet. Adequate protein also protects lean mass, which affects how the results look and hold.
- Activity — especially strength training. Movement adds to the deficit; resistance work preserves muscle so more of the loss is fat.
- Consistency and plateaus. Missed doses, long titration pauses, and giving up during a normal plateau all pull the final number down. The people who hit trial-like results mostly stayed the course.
Keeping the weight off
The uncomfortable part of the data: for most people, stopping means regaining some of it. In the SURMOUNT-4 maintenance study, people who switched to placebo regained about 14% of body weight over the following year (⚠ verify), while those who stayed on Zepbound kept losing.
That’s not a failure of the drug — it’s how obesity behaves as a chronic condition. Zepbound was studied as a long-term treatment, not a course you finish. Realistic planning means thinking about maintenance dosing and durable diet and strength habits from the start, not treating month 12 as a finish line. If side effects are part of your calculus, the side effects page covers what tends to ease over time and what doesn’t.
Estimate your own results
Trial averages are a starting point, not your number. To see a personalized range based on your starting weight and target dose, use the calculator — then talk the plan through with a prescriber.
Zepbound: the complete guide How tirzepatide works, full trial results, dosing, cost, and how to get itThis page is informational and is not medical advice. Trial figures describe supervised study participants, not expected individual results, and every non-trial figure here is a draft pending verification. Talk to a licensed clinician about what’s realistic for you. See our medical disclaimer and GLP-1 safety information.